larrylim11的个人主页 - 老虎社区

larrylim11

larrylim11

暂无个人介绍

IP属地：未知

2关注

1粉丝

0主题

0勋章

2021-12-23

//@iNights: NiceWhoa

Moderna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote>

2021-12-23

Yea..

2021-12-23

Wow..

Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote>

2021-12-23

Keep going!

抱歉，原内容已删除

2021-12-23

Market will go back up!

2021-12-23

Good stuff

Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>

2021-12-18

Good stuff

2021-12-17

Good stuff

CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&J)</blockquote>

2021-12-17

Good stuff!

抱歉，原内容已删除

2021-11-06

Whee!

@小虎活动:[Halloween Game] Trade or Treat!

2021-11-04

Yes!

@小虎活动:[Halloween Game] Trade or Treat!

2021-11-03

Woo hoo!

@小虎活动:[Halloween Game] Trade or Treat!

2021-07-14

Good stuff

抱歉，原内容已删除

2021-07-08

Oh no..

抱歉，原内容已删除

2021-06-29

Good stuff!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4087961992375920","uuid":"4087961992375920","gmtCreate":1624859373762,"gmtModify":1624976947105,"name":"larrylim11","pinyin":"larrylim11","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.25","exceedPercentage":"93.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.14","exceedPercentage":"93.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":13,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691413731,"gmtCreate":1640226836214,"gmtModify":1640226836302,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","listText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","text":"//@iNights: NiceWhoa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413731","repostId":"1181809495","repostType":4,"repost":{"id":"1181809495","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640225885,"share":"https://www.laohu8.com/m/news/1181809495?lang=zh_CN&edition=full","pubTime":"2021-12-23 10:18","market":"us","language":"en","title":"Moderna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1181809495","media":"Benzinga","summary":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was","content":"<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p><p><blockquote><b>现代公司</b>周三股价走低，并跌向支撑位。</blockquote></p><p> The stock was trending on social media sites throughout the day after the stock saw some movement.</p><p><blockquote>在该股出现一些波动后，该股全天都在社交媒体网站上流行。</blockquote></p><p> Moderna was down 6.26% at $251.36 at market close Wednesday.</p><p><blockquote>Moderna周三收盘下跌6.26%，至251.36美元。</blockquote></p><p> <b>Moderna Daily Chart Analysis</b></p><p><blockquote><b>Moderna日线图分析</b></blockquote></p><p> <ul>  <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>  <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>  <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li> </ul> <img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>股价下跌至支撑位，交易员看涨期权为上升三角形形态。未来某个时候，股价可能会再次从较高的低点支撑位反弹。阻力位在460美元附近。</li><li>该股交易价格低于50日移动平均线（绿色），但高于200日移动平均线（蓝色）。这表明该股可能处于盘整期，50日均线可能作为阻力，而200日均线可能作为支撑。</li><li>过去几天，相对强弱指数(RSI)一直在小幅走低，目前为41。这表明卖方在该股中占主导地位，并且略微压倒了买方。</li></ul></blockquote></p><p> <b>What’s Next For Moderna?</b></p><p><blockquote><b>Moderna的下一步是什么？</b></blockquote></p><p> Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p><p><blockquote>Moderna在过去几天出现了下跌，并正在回落到更高的低点趋势线。如果该区域能够再次反弹，价格可能会再次开始走向阻力。多头正在寻找更高的低点继续形成，以使该股保持看涨趋势。空头希望看到该股跌破这一趋势线，并希望价格开始向更低的高点移动。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-23 10:18</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p><p><blockquote><b>现代公司</b>周三股价走低，并跌向支撑位。</blockquote></p><p> The stock was trending on social media sites throughout the day after the stock saw some movement.</p><p><blockquote>在该股出现一些波动后，该股全天都在社交媒体网站上流行。</blockquote></p><p> Moderna was down 6.26% at $251.36 at market close Wednesday.</p><p><blockquote>Moderna周三收盘下跌6.26%，至251.36美元。</blockquote></p><p> <b>Moderna Daily Chart Analysis</b></p><p><blockquote><b>Moderna日线图分析</b></blockquote></p><p> <ul>  <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>  <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>  <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li> </ul> <img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>股价下跌至支撑位，交易员看涨期权为上升三角形形态。未来某个时候，股价可能会再次从较高的低点支撑位反弹。阻力位在460美元附近。</li><li>该股交易价格低于50日移动平均线（绿色），但高于200日移动平均线（蓝色）。这表明该股可能处于盘整期，50日均线可能作为阻力，而200日均线可能作为支撑。</li><li>过去几天，相对强弱指数(RSI)一直在小幅走低，目前为41。这表明卖方在该股中占主导地位，并且略微压倒了买方。</li></ul></blockquote></p><p> <b>What’s Next For Moderna?</b></p><p><blockquote><b>Moderna的下一步是什么？</b></blockquote></p><p> Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p><p><blockquote>Moderna在过去几天出现了下跌，并正在回落到更高的低点趋势线。如果该区域能够再次反弹，价格可能会再次开始走向阻力。多头正在寻找更高的低点继续形成，以使该股保持看涨趋势。空头希望看到该股跌破这一趋势线，并希望价格开始向更低的高点移动。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181809495","content_text":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was trending on social media sites throughout the day after the stock saw some movement.\nModerna was down 6.26% at $251.36 at market close Wednesday.\nModerna Daily Chart Analysis\n\nShares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.\nThe stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.\nThe Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.\n\n\nWhat’s Next For Moderna?\nModerna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413302,"gmtCreate":1640226771801,"gmtModify":1640226771801,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yea..","listText":"Yea..","text":"Yea..","images":[{"img":"https://static.tigerbbs.com/e20070159fdd392e5a013b6c48806820","width":"1080","height":"1309"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413302","isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":691419155,"gmtCreate":1640226681816,"gmtModify":1640226681874,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Wow..","listText":"Wow..","text":"Wow..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691419155","repostId":"1141555850","repostType":4,"repost":{"id":"1141555850","kind":"news","pubTimestamp":1640226334,"share":"https://www.laohu8.com/m/news/1141555850?lang=zh_CN&edition=full","pubTime":"2021-12-23 10:25","market":"us","language":"en","title":"Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141555850","media":"TheStreet","summary":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely alr","content":"<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p><p><blockquote>从长远来看，苹果的电动汽车催化剂可能有助于提高回报。但在短期内，它可能已经反映在苹果公司的股票中。</blockquote></p><p> Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p><p><blockquote>上周，我们分析了苹果股票及其元宇宙催化剂。具体来说，为什么这家科技巨头进军AR（增强现实）和VR（虚拟现实）硬件最多只能给股价带来小幅提振。</blockquote></p><p> Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p><p><blockquote>现在，让我们看看一个潜在的催化剂，它可能更像是一个推动因素：该公司的苹果汽车项目。如果其开发和推出成功，相信这款全自动电动汽车(EV)可以与Lucid和Rivian等该领域的顶级早期品牌竞争并不牵强。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果汽车原型。</span></p></blockquote></p><p> Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p><p><blockquote>不仅如此，苹果汽车还可能有机会从目前的领导者特斯拉手中夺取大量市场份额。然而，在下买入订单之前，让我们仔细看看这种催化剂及其对苹果股票的潜在近期和长期影响。</blockquote></p><p> <b>AAPL Stock and its Apple Car Catalyst</b></p><p><blockquote><b>AAPL股票及其苹果汽车催化剂</b></blockquote></p><p> Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p><p><blockquote>在深入研究之前，先简要介绍一下苹果及其电动汽车项目。多年来，该公司一直致力于开发电动汽车。</blockquote></p><p> Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p><p><blockquote>之前，它既设计了一款有限的自动驾驶汽车，也设计了一款全自动驾驶汽车。同时做这两个项目是有意义的。这将使其能够在完全自主功能可用之前推出电动汽车。</blockquote></p><p> But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p><p><blockquote>但现在，随着负责该项目的新领导人（Kevin Lynch），苹果正在将所有鸡蛋放在完全自主的篮子里。该公司加快了时间表，目标是2025年发布全自动电动汽车。</blockquote></p><p> Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p><p><blockquote>鉴于其过去的记录，人们对苹果将在这一最后期限前完成并在不到四年的时间里拿出一个可能的“特斯拉杀手”抱有很高的期望。然而，这并不是说这已成定局。</blockquote></p><p> <b>The Apple Maven’s Take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p> Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p><p><blockquote>与元宇宙催化剂不同，苹果汽车可能会提供更大的上涨潜力。正如摩根士丹利(Morgan Stanley)的凯蒂·休伯蒂(Katy Huberty)去年11月所言，其推出全自动驾驶电动汽车最终可能会使其收入和市值翻一番。</blockquote></p><p> The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p><p><blockquote>这位卖方分析师指出了许多因素来支持她的观点，其中之一是该公司庞大的客户群。此外，还有苹果过去潜入未知领域的成功。例如，该公司在推出iPhone时是移动通信设备的后来者，但目前它占据了23%的市场份额，并且还在增长。</blockquote></p><p> That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p><p><blockquote>也就是说，虽然苹果汽车取得成功的机会很大，但在进入交付阶段时仍可能遇到困难。事实上，它现在已经在应对一些障碍，从最近该项目将关键工程师输给竞争对手的消息就可以看出。</blockquote></p><p> On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p><p><blockquote>最重要的是，由于苹果公司股票的预期市盈率已经很高，这一催化剂可能已经计入其估值中。休伯蒂女士认为电动汽车有一天可能会使股价翻倍。尽管如此，她目前每股200美元的目标价比AAPL今天每股170美元的交易价格高出不到20%，这表明苹果汽车对该股的大部分上涨可能要到2022年之后才会出现。</blockquote></p><p> Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p><p><blockquote>底线：苹果汽车可能会分别帮助公司和股票实现稳健的长期财务业绩和市场收益。与此同时，它可能无法在未来几个月给股价带来大的震动。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-23 10:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p><p><blockquote>从长远来看，苹果的电动汽车催化剂可能有助于提高回报。但在短期内，它可能已经反映在苹果公司的股票中。</blockquote></p><p> Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p><p><blockquote>上周，我们分析了苹果股票及其元宇宙催化剂。具体来说，为什么这家科技巨头进军AR（增强现实）和VR（虚拟现实）硬件最多只能给股价带来小幅提振。</blockquote></p><p> Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p><p><blockquote>现在，让我们看看一个潜在的催化剂，它可能更像是一个推动因素：该公司的苹果汽车项目。如果其开发和推出成功，相信这款全自动电动汽车(EV)可以与Lucid和Rivian等该领域的顶级早期品牌竞争并不牵强。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果汽车原型。</span></p></blockquote></p><p> Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p><p><blockquote>不仅如此，苹果汽车还可能有机会从目前的领导者特斯拉手中夺取大量市场份额。然而，在下买入订单之前，让我们仔细看看这种催化剂及其对苹果股票的潜在近期和长期影响。</blockquote></p><p> <b>AAPL Stock and its Apple Car Catalyst</b></p><p><blockquote><b>AAPL股票及其苹果汽车催化剂</b></blockquote></p><p> Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p><p><blockquote>在深入研究之前，先简要介绍一下苹果及其电动汽车项目。多年来，该公司一直致力于开发电动汽车。</blockquote></p><p> Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p><p><blockquote>之前，它既设计了一款有限的自动驾驶汽车，也设计了一款全自动驾驶汽车。同时做这两个项目是有意义的。这将使其能够在完全自主功能可用之前推出电动汽车。</blockquote></p><p> But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p><p><blockquote>但现在，随着负责该项目的新领导人（Kevin Lynch），苹果正在将所有鸡蛋放在完全自主的篮子里。该公司加快了时间表，目标是2025年发布全自动电动汽车。</blockquote></p><p> Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p><p><blockquote>鉴于其过去的记录，人们对苹果将在这一最后期限前完成并在不到四年的时间里拿出一个可能的“特斯拉杀手”抱有很高的期望。然而，这并不是说这已成定局。</blockquote></p><p> <b>The Apple Maven’s Take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p> Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p><p><blockquote>与元宇宙催化剂不同，苹果汽车可能会提供更大的上涨潜力。正如摩根士丹利(Morgan Stanley)的凯蒂·休伯蒂(Katy Huberty)去年11月所言，其推出全自动驾驶电动汽车最终可能会使其收入和市值翻一番。</blockquote></p><p> The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p><p><blockquote>这位卖方分析师指出了许多因素来支持她的观点，其中之一是该公司庞大的客户群。此外，还有苹果过去潜入未知领域的成功。例如，该公司在推出iPhone时是移动通信设备的后来者，但目前它占据了23%的市场份额，并且还在增长。</blockquote></p><p> That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p><p><blockquote>也就是说，虽然苹果汽车取得成功的机会很大，但在进入交付阶段时仍可能遇到困难。事实上，它现在已经在应对一些障碍，从最近该项目将关键工程师输给竞争对手的消息就可以看出。</blockquote></p><p> On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p><p><blockquote>最重要的是，由于苹果公司股票的预期市盈率已经很高，这一催化剂可能已经计入其估值中。休伯蒂女士认为电动汽车有一天可能会使股价翻倍。尽管如此，她目前每股200美元的目标价比AAPL今天每股170美元的交易价格高出不到20%，这表明苹果汽车对该股的大部分上涨可能要到2022年之后才会出现。</blockquote></p><p> Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p><p><blockquote>底线：苹果汽车可能会分别帮助公司和股票实现稳健的长期财务业绩和市场收益。与此同时，它可能无法在未来几个月给股价带来大的震动。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141555850","content_text":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares only a slight boost, at best.\nNow, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid and Rivian, a run for their money.\nFigure 1: Apple Car prototype.\nNot only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.\nAAPL Stock and its Apple Car Catalyst\nBefore diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.\nBefore, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.\nBut now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.\nGiven its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.\nThe Apple Maven’s Take\nUnlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately double both its revenue and market cap.\nThe sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds 23% of the market and growing.\nThat said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project losing key engineers to rivals.\nOn top of this, with AAPL stock already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.\nBottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.","news_type":1,"symbols_score_info":{"AAPL":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691410388,"gmtCreate":1640226641093,"gmtModify":1640226641093,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Keep going!","listText":"Keep going!","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691410388","repostId":"2193113147","repostType":4,"isVote":1,"tweetType":1,"viewCount":2830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691292885,"gmtCreate":1640191003765,"gmtModify":1640191003765,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Market will go back up!","listText":"Market will go back up!","text":"Market will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691292885","isVote":1,"tweetType":1,"viewCount":2074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691293403,"gmtCreate":1640190705944,"gmtModify":1640190719185,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691293403","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=zh_CN&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 23:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":3433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699862235,"gmtCreate":1639782488972,"gmtModify":1639782488972,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699862235","isVote":1,"tweetType":1,"viewCount":2050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690559633,"gmtCreate":1639696351853,"gmtModify":1639696351937,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff&nbsp;","listText":"Good stuff&nbsp;","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690559633","repostId":"1154960652","repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=zh_CN&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&amp;Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&amp;J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&amp;J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-17 07:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&amp;Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&amp;J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&amp;J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690550452,"gmtCreate":1639696288846,"gmtModify":1639696289837,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690550452","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":2438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842621749,"gmtCreate":1636171939170,"gmtModify":1636171939265,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Whee!","listText":"Whee!","text":"Whee!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842621749","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848103890,"gmtCreate":1635980926483,"gmtModify":1635980926610,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848103890","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841123231,"gmtCreate":1635897114472,"gmtModify":1635897114472,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Woo hoo!","listText":"Woo hoo!","text":"Woo hoo!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841123231","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144370844,"gmtCreate":1626270128588,"gmtModify":1633928446212,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144370844","repostId":"1158673076","repostType":4,"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143020380,"gmtCreate":1625753028240,"gmtModify":1633937686390,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Oh no..","listText":"Oh no..","text":"Oh no..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143020380","repostId":"1195364777","repostType":4,"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159252598,"gmtCreate":1624971958014,"gmtModify":1633946386466,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159252598","repostId":"1100563900","repostType":2,"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":691410388,"gmtCreate":1640226641093,"gmtModify":1640226641093,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Keep going!","listText":"Keep going!","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691410388","repostId":"2193113147","repostType":4,"isVote":1,"tweetType":1,"viewCount":2830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691293403,"gmtCreate":1640190705944,"gmtModify":1640190719185,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691293403","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=zh_CN&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么Paychex股价今天创下历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 23:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>在该公司公布好于预期的2022财年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex公布的季度调整后每股收益为91美分，超出了每股80美分的预期。该公司公布季度营收为11.1亿美元，超出预期的10.6亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex表示，预计2022财年收入增长10%至11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了2022财年第二季度强劲的财务业绩，总收入增长13%，稀释后每股收益增长21%。业绩是由我们客户群中员工的增长以及持续强劲的销售增长和客户保留率推动的，”说<b>马丁·穆奇</b>，Paychex董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex在52周内的交易价格低至85.30美元。周三交易时段创下52周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨5.54%，至133.44美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":3433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690559633,"gmtCreate":1639696351853,"gmtModify":1639696351937,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff&nbsp;","listText":"Good stuff&nbsp;","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690559633","repostId":"1154960652","repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=zh_CN&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&amp;Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&amp;J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&amp;J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&amp;J)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-17 07:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&amp;Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&amp;J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&amp;J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691419155,"gmtCreate":1640226681816,"gmtModify":1640226681874,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Wow..","listText":"Wow..","text":"Wow..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691419155","repostId":"1141555850","repostType":4,"repost":{"id":"1141555850","kind":"news","pubTimestamp":1640226334,"share":"https://www.laohu8.com/m/news/1141555850?lang=zh_CN&edition=full","pubTime":"2021-12-23 10:25","market":"us","language":"en","title":"Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141555850","media":"TheStreet","summary":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely alr","content":"<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p><p><blockquote>从长远来看，苹果的电动汽车催化剂可能有助于提高回报。但在短期内，它可能已经反映在苹果公司的股票中。</blockquote></p><p> Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p><p><blockquote>上周，我们分析了苹果股票及其元宇宙催化剂。具体来说，为什么这家科技巨头进军AR（增强现实）和VR（虚拟现实）硬件最多只能给股价带来小幅提振。</blockquote></p><p> Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p><p><blockquote>现在，让我们看看一个潜在的催化剂，它可能更像是一个推动因素：该公司的苹果汽车项目。如果其开发和推出成功，相信这款全自动电动汽车(EV)可以与Lucid和Rivian等该领域的顶级早期品牌竞争并不牵强。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果汽车原型。</span></p></blockquote></p><p> Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p><p><blockquote>不仅如此，苹果汽车还可能有机会从目前的领导者特斯拉手中夺取大量市场份额。然而，在下买入订单之前，让我们仔细看看这种催化剂及其对苹果股票的潜在近期和长期影响。</blockquote></p><p> <b>AAPL Stock and its Apple Car Catalyst</b></p><p><blockquote><b>AAPL股票及其苹果汽车催化剂</b></blockquote></p><p> Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p><p><blockquote>在深入研究之前，先简要介绍一下苹果及其电动汽车项目。多年来，该公司一直致力于开发电动汽车。</blockquote></p><p> Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p><p><blockquote>之前，它既设计了一款有限的自动驾驶汽车，也设计了一款全自动驾驶汽车。同时做这两个项目是有意义的。这将使其能够在完全自主功能可用之前推出电动汽车。</blockquote></p><p> But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p><p><blockquote>但现在，随着负责该项目的新领导人（Kevin Lynch），苹果正在将所有鸡蛋放在完全自主的篮子里。该公司加快了时间表，目标是2025年发布全自动电动汽车。</blockquote></p><p> Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p><p><blockquote>鉴于其过去的记录，人们对苹果将在这一最后期限前完成并在不到四年的时间里拿出一个可能的“特斯拉杀手”抱有很高的期望。然而，这并不是说这已成定局。</blockquote></p><p> <b>The Apple Maven’s Take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p> Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p><p><blockquote>与元宇宙催化剂不同，苹果汽车可能会提供更大的上涨潜力。正如摩根士丹利(Morgan Stanley)的凯蒂·休伯蒂(Katy Huberty)去年11月所言，其推出全自动驾驶电动汽车最终可能会使其收入和市值翻一番。</blockquote></p><p> The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p><p><blockquote>这位卖方分析师指出了许多因素来支持她的观点，其中之一是该公司庞大的客户群。此外，还有苹果过去潜入未知领域的成功。例如，该公司在推出iPhone时是移动通信设备的后来者，但目前它占据了23%的市场份额，并且还在增长。</blockquote></p><p> That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p><p><blockquote>也就是说，虽然苹果汽车取得成功的机会很大，但在进入交付阶段时仍可能遇到困难。事实上，它现在已经在应对一些障碍，从最近该项目将关键工程师输给竞争对手的消息就可以看出。</blockquote></p><p> On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p><p><blockquote>最重要的是，由于苹果公司股票的预期市盈率已经很高，这一催化剂可能已经计入其估值中。休伯蒂女士认为电动汽车有一天可能会使股价翻倍。尽管如此，她目前每股200美元的目标价比AAPL今天每股170美元的交易价格高出不到20%，这表明苹果汽车对该股的大部分上涨可能要到2022年之后才会出现。</blockquote></p><p> Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p><p><blockquote>底线：苹果汽车可能会分别帮助公司和股票实现稳健的长期财务业绩和市场收益。与此同时，它可能无法在未来几个月给股价带来大的震动。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’<blockquote>苹果股票：苹果汽车会成为最终的“特斯拉杀手”吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-23 10:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p><p><blockquote>从长远来看，苹果的电动汽车催化剂可能有助于提高回报。但在短期内，它可能已经反映在苹果公司的股票中。</blockquote></p><p> Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p><p><blockquote>上周，我们分析了苹果股票及其元宇宙催化剂。具体来说，为什么这家科技巨头进军AR（增强现实）和VR（虚拟现实）硬件最多只能给股价带来小幅提振。</blockquote></p><p> Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p><p><blockquote>现在，让我们看看一个潜在的催化剂，它可能更像是一个推动因素：该公司的苹果汽车项目。如果其开发和推出成功，相信这款全自动电动汽车(EV)可以与Lucid和Rivian等该领域的顶级早期品牌竞争并不牵强。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果汽车原型。</span></p></blockquote></p><p> Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p><p><blockquote>不仅如此，苹果汽车还可能有机会从目前的领导者特斯拉手中夺取大量市场份额。然而，在下买入订单之前，让我们仔细看看这种催化剂及其对苹果股票的潜在近期和长期影响。</blockquote></p><p> <b>AAPL Stock and its Apple Car Catalyst</b></p><p><blockquote><b>AAPL股票及其苹果汽车催化剂</b></blockquote></p><p> Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p><p><blockquote>在深入研究之前，先简要介绍一下苹果及其电动汽车项目。多年来，该公司一直致力于开发电动汽车。</blockquote></p><p> Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p><p><blockquote>之前，它既设计了一款有限的自动驾驶汽车，也设计了一款全自动驾驶汽车。同时做这两个项目是有意义的。这将使其能够在完全自主功能可用之前推出电动汽车。</blockquote></p><p> But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p><p><blockquote>但现在，随着负责该项目的新领导人（Kevin Lynch），苹果正在将所有鸡蛋放在完全自主的篮子里。该公司加快了时间表，目标是2025年发布全自动电动汽车。</blockquote></p><p> Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p><p><blockquote>鉴于其过去的记录，人们对苹果将在这一最后期限前完成并在不到四年的时间里拿出一个可能的“特斯拉杀手”抱有很高的期望。然而，这并不是说这已成定局。</blockquote></p><p> <b>The Apple Maven’s Take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p> Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p><p><blockquote>与元宇宙催化剂不同，苹果汽车可能会提供更大的上涨潜力。正如摩根士丹利(Morgan Stanley)的凯蒂·休伯蒂(Katy Huberty)去年11月所言，其推出全自动驾驶电动汽车最终可能会使其收入和市值翻一番。</blockquote></p><p> The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p><p><blockquote>这位卖方分析师指出了许多因素来支持她的观点，其中之一是该公司庞大的客户群。此外，还有苹果过去潜入未知领域的成功。例如，该公司在推出iPhone时是移动通信设备的后来者，但目前它占据了23%的市场份额，并且还在增长。</blockquote></p><p> That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p><p><blockquote>也就是说，虽然苹果汽车取得成功的机会很大，但在进入交付阶段时仍可能遇到困难。事实上，它现在已经在应对一些障碍，从最近该项目将关键工程师输给竞争对手的消息就可以看出。</blockquote></p><p> On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p><p><blockquote>最重要的是，由于苹果公司股票的预期市盈率已经很高，这一催化剂可能已经计入其估值中。休伯蒂女士认为电动汽车有一天可能会使股价翻倍。尽管如此，她目前每股200美元的目标价比AAPL今天每股170美元的交易价格高出不到20%，这表明苹果汽车对该股的大部分上涨可能要到2022年之后才会出现。</blockquote></p><p> Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p><p><blockquote>底线：苹果汽车可能会分别帮助公司和股票实现稳健的长期财务业绩和市场收益。与此同时，它可能无法在未来几个月给股价带来大的震动。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141555850","content_text":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares only a slight boost, at best.\nNow, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid and Rivian, a run for their money.\nFigure 1: Apple Car prototype.\nNot only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.\nAAPL Stock and its Apple Car Catalyst\nBefore diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.\nBefore, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.\nBut now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.\nGiven its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.\nThe Apple Maven’s Take\nUnlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately double both its revenue and market cap.\nThe sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds 23% of the market and growing.\nThat said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project losing key engineers to rivals.\nOn top of this, with AAPL stock already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.\nBottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.","news_type":1,"symbols_score_info":{"AAPL":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413731,"gmtCreate":1640226836214,"gmtModify":1640226836302,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","listText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","text":"//@iNights: NiceWhoa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413731","repostId":"1181809495","repostType":4,"repost":{"id":"1181809495","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640225885,"share":"https://www.laohu8.com/m/news/1181809495?lang=zh_CN&edition=full","pubTime":"2021-12-23 10:18","market":"us","language":"en","title":"Moderna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1181809495","media":"Benzinga","summary":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was","content":"<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p><p><blockquote><b>现代公司</b>周三股价走低，并跌向支撑位。</blockquote></p><p> The stock was trending on social media sites throughout the day after the stock saw some movement.</p><p><blockquote>在该股出现一些波动后，该股全天都在社交媒体网站上流行。</blockquote></p><p> Moderna was down 6.26% at $251.36 at market close Wednesday.</p><p><blockquote>Moderna周三收盘下跌6.26%，至251.36美元。</blockquote></p><p> <b>Moderna Daily Chart Analysis</b></p><p><blockquote><b>Moderna日线图分析</b></blockquote></p><p> <ul>  <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>  <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>  <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li> </ul> <img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>股价下跌至支撑位，交易员看涨期权为上升三角形形态。未来某个时候，股价可能会再次从较高的低点支撑位反弹。阻力位在460美元附近。</li><li>该股交易价格低于50日移动平均线（绿色），但高于200日移动平均线（蓝色）。这表明该股可能处于盘整期，50日均线可能作为阻力，而200日均线可能作为支撑。</li><li>过去几天，相对强弱指数(RSI)一直在小幅走低，目前为41。这表明卖方在该股中占主导地位，并且略微压倒了买方。</li></ul></blockquote></p><p> <b>What’s Next For Moderna?</b></p><p><blockquote><b>Moderna的下一步是什么？</b></blockquote></p><p> Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p><p><blockquote>Moderna在过去几天出现了下跌，并正在回落到更高的低点趋势线。如果该区域能够再次反弹，价格可能会再次开始走向阻力。多头正在寻找更高的低点继续形成，以使该股保持看涨趋势。空头希望看到该股跌破这一趋势线，并希望价格开始向更低的高点移动。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Is Dipping: What's Next?<blockquote>Moderna正在下跌：下一步是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-23 10:18</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p><p><blockquote><b>现代公司</b>周三股价走低，并跌向支撑位。</blockquote></p><p> The stock was trending on social media sites throughout the day after the stock saw some movement.</p><p><blockquote>在该股出现一些波动后，该股全天都在社交媒体网站上流行。</blockquote></p><p> Moderna was down 6.26% at $251.36 at market close Wednesday.</p><p><blockquote>Moderna周三收盘下跌6.26%，至251.36美元。</blockquote></p><p> <b>Moderna Daily Chart Analysis</b></p><p><blockquote><b>Moderna日线图分析</b></blockquote></p><p> <ul>  <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>  <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>  <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li> </ul> <img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>股价下跌至支撑位，交易员看涨期权为上升三角形形态。未来某个时候，股价可能会再次从较高的低点支撑位反弹。阻力位在460美元附近。</li><li>该股交易价格低于50日移动平均线（绿色），但高于200日移动平均线（蓝色）。这表明该股可能处于盘整期，50日均线可能作为阻力，而200日均线可能作为支撑。</li><li>过去几天，相对强弱指数(RSI)一直在小幅走低，目前为41。这表明卖方在该股中占主导地位，并且略微压倒了买方。</li></ul></blockquote></p><p> <b>What’s Next For Moderna?</b></p><p><blockquote><b>Moderna的下一步是什么？</b></blockquote></p><p> Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p><p><blockquote>Moderna在过去几天出现了下跌，并正在回落到更高的低点趋势线。如果该区域能够再次反弹，价格可能会再次开始走向阻力。多头正在寻找更高的低点继续形成，以使该股保持看涨趋势。空头希望看到该股跌破这一趋势线，并希望价格开始向更低的高点移动。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181809495","content_text":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was trending on social media sites throughout the day after the stock saw some movement.\nModerna was down 6.26% at $251.36 at market close Wednesday.\nModerna Daily Chart Analysis\n\nShares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.\nThe stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.\nThe Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.\n\n\nWhat’s Next For Moderna?\nModerna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413302,"gmtCreate":1640226771801,"gmtModify":1640226771801,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Yea..","listText":"Yea..","text":"Yea..","images":[{"img":"https://static.tigerbbs.com/e20070159fdd392e5a013b6c48806820","width":"1080","height":"1309"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413302","isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":691292885,"gmtCreate":1640191003765,"gmtModify":1640191003765,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Market will go back up!","listText":"Market will go back up!","text":"Market will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691292885","isVote":1,"tweetType":1,"viewCount":2074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699862235,"gmtCreate":1639782488972,"gmtModify":1639782488972,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699862235","isVote":1,"tweetType":1,"viewCount":2050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690550452,"gmtCreate":1639696288846,"gmtModify":1639696289837,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690550452","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":2438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842621749,"gmtCreate":1636171939170,"gmtModify":1636171939265,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087961992375920","idStr":"4087961992375920"},"themes":[],"htmlText":"Whee!","listText":"Whee!","text":"Whee!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842621749","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}